Sickle Cell Disease QoL and Life Expectancy
Read More
Diagnosing and Assessing AD in Patients With Skin of Color
Clinical Presentation of AD in Skin of Color
Atopic Dermatitis in Diverse Racial and Ethnic Groups
Impact of Atopic Dermatitis on Quality of Life
Presentation of Atopic Dermatitis in Adults and Pediatrics
Understanding the Pathophysiology of Atopic Dermatitis
Discussing Iodine-Refractory DTC With Patients
Clinical Scenarios to Consider for RAI-Refractory DTC
Thyrotropin Suppression as DTC Treatment Option
Role of Radioiodine Treatment in DTC
DTC: Histological Subtypes and Tumor Differentiation
Differentiated Thyroid Cancer: Increasing Incidence
Management of T2DM During COVID and Future Directions
Underutilization of GLP1 Receptor Agonists in T2DM Therapy
GLP1 Receptor Agonists in Clinical Practice for T2DM
Management of Nausea Resulting from GLP1 Agonists for T2DM
GLP-1 Receptor Agonist Treatment Options for T2D
Patient Factors and CV Risk in Type 2 Diabetes
New Available Treatment Options for Type 2 Diabetes
ADA Clinical Guideline Overview for Diabetes
Strains of C. Difficile
Managing Community-Onset C. Difficile
Managing Novel Therapy AEs in Sickle Cell Disease
Voxelotor and Crizanlizumab: Safety and Tolerability
Treatment Goals and Role of New Therapies for SCD
Clinical Implications and Evidence for the Treatment of Sickle Cell
Efficacy and Safety from the 72-Week Analysis of the HOPE Study
Takeaways from the 52-Week C-axSpAnd Trial
Takeaways from Four-Year RAPID-axSpA Data